AGIOS PHARMACEUTICALS, INC. (AGIO)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 20M 40M 60M Q3 '21: 0 Q4 '21: 0 Q1 '22: 832K Q2 '22: 5.6M Q3 '22: 3.5M Q4 '22: 4.3M Q1 '23: 5.6M Q2 '23: 6.7M Q3 '23: 7.4M Q4 '23: 7.1M Q1 '24: 8.2M Q2 '24: 8.6M Q3 '24: 9M Q4 '24: 10.7M Q1 '25: 8.7M Q2 '25: 12.5M Q3 '25: 12.9M Q4 '25: 20M Q1 '26: 20.7M Q2 '26: 44.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

0 15M 30M 45M Q3 '21: 0 Q4 '21: 0 Q1 '22: 493K Q2 '22: 5.1M Q3 '22: 3M Q4 '22: 3.9M Q1 '23: 5.1M Q2 '23: 5.6M Q3 '23: 6.8M Q4 '23: 6.5M Q1 '24: 7.6M Q2 '24: 7.1M Q3 '24: 8.2M Q4 '24: 9.5M Q1 '25: 7.6M Q2 '25: 10.8M Q3 '25: 11.2M Q4 '25: 18.1M Q1 '26: 19.4M Q2 '26: 41.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-150M -100M -50M 0 50M 100M 150M Q3 '21: -91.2M Q4 '21: -104.8M Q1 '22: -101.1M Q2 '22: -97.6M Q3 '22: -91.1M Q4 '22: -99.2M Q1 '23: -90.6M Q2 '23: -93.7M Q3 '23: -100.9M Q4 '23: -106.3M Q1 '24: -92.1M Q2 '24: -105.8M Q3 '24: -102.8M Q4 '24: -125M Q1 '25: -106.6M Q2 '25: -127.1M Q3 '25: -116.9M Q4 '25: -121.6M Q1 '26: -110M Q2 '26: -110.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-350M 0 350M 700M 1.1B Q3 '21: -88.8M Q4 '21: -94.6M Q1 '22: -94.8M Q2 '22: -91.8M Q3 '22: -81.7M Q4 '22: 36.5M Q1 '23: -81M Q2 '23: -83.8M Q3 '23: -91.3M Q4 '23: -95.9M Q1 '24: -81.5M Q2 '24: -96.1M Q3 '24: 947.9M Q4 '24: -96.5M Q1 '25: -89.3M Q2 '25: -112M Q3 '25: -103.4M Q4 '25: -108M Q1 '26: -99.1M Q2 '26: -100.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 1.5M 3M 4.5M Q3 '21: 0 Q4 '21: 0 Q1 '22: 339K Q2 '22: 435K Q3 '22: 517K Q4 '22: 413K Q1 '23: 554K Q2 '23: 1.1M Q3 '23: 633K Q4 '23: 586K Q1 '24: 627K Q2 '24: 1.5M Q3 '24: 783K Q4 '24: 1.3M Q1 '25: 1.1M Q2 '25: 1.7M Q3 '25: 1.7M Q4 '25: 1.9M Q1 '26: 1.3M Q2 '26: 3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-150M -100M -50M 0 50M 100M 150M Q3 '21: -85.2M Q4 '21: -84.1M Q1 '22: -97.7M Q2 '22: -74.2M Q3 '22: -71.4M Q4 '22: -66.2M Q1 '23: -95.2M Q2 '23: -66.7M Q3 '23: -61.6M Q4 '23: -72.5M Q1 '24: -99.9M Q2 '24: -72.6M Q3 '24: -84.2M Q4 '24: -133.2M Q1 '25: -111.5M Q2 '25: -77.1M Q3 '25: -88.2M Q4 '25: -96.2M Q1 '26: -118.9M Q2 '26: -57.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-150M -100M -50M 0 50M 100M 150M Q3 '21: -85.2M Q4 '21: -88.6M Q1 '22: -100.5M Q2 '22: -76.2M Q3 '22: -71.4M Q4 '22: -66.3M Q1 '23: -95.6M Q2 '23: -66.8M Q3 '23: -62M Q4 '23: -72.7M Q1 '24: -100M Q2 '24: -72.7M Q3 '24: -84.6M Q4 '24: -134.1M Q1 '25: -112.3M Q2 '25: -78M Q3 '25: -89.7M Q4 '25: -97.3M Q1 '26: -119.7M Q2 '26: -58.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 25M 50M 75M Q1 '20: 68.6M Q2 '20: 69M Q3 '20: 69.1M Q1 '21: 69.5M Q2 '21: 61.1M Q3 '21: 57M Q1 '22: 54.6M Q2 '22: 54.8M Q3 '22: 54.8M Q1 '23: 55.3M Q2 '23: 55.6M Q3 '23: 55.8M Q1 '24: 56.4M Q2 '24: 56.8M Q3 '24: 58.4M Q1 '25: 57.5M Q2 '25: 57.9M Q3 '25: 58.1M Q1 '26: 58.8M Q2 '26: 59.5M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-8.00 0.00 8.00 16.00 24.00 Q3 '21: 22.57 Q4 '21: 22.24 Q1 '22: -6.45 Q2 '22: -6.72 Q3 '22: -6.65 Q4 '22: -4.23 Q1 '23: -3.96 Q2 '23: -3.79 Q3 '23: -3.94 Q4 '23: -6.34 Q1 '24: -6.32 Q2 '24: -6.50 Q3 '24: 11.36 Q4 '24: 11.64 Q1 '25: 11.54 Q2 '25: 11.30 Q3 '25: -6.70 Q4 '25: -7.11 Q1 '26: -7.25 Q2 '26: -7.01 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.